Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 6 | 11 |
List of Tables | 9 | 4 |
List of Figures | 13 | 4 |
Introduction | 17 | 1 |
GlobalData Report Guidance | 17 | 1 |
Overview of Pharmaceutical and Medical Device Markets | 18 | 102 |
Pharmaceutical Market | 18 | 1 |
Market Overview | 18 | 6 |
Pharmaceutical Imports and Exports | 24 | 1 |
Supply Channels | 24 | 1 |
Market Segments | 25 | 1 |
Generic Drugs | 25 | 2 |
Biologics/Biosimilars | 27 | 1 |
Over-the-Counter Drugs | 27 | 2 |
Major Therapeutic Areas | 29 | 1 |
Cardiovascular Diseases | 29 | 1 |
Cancer | 30 | 1 |
Respiratory Disorders | 30 | 1 |
Diabetes | 31 | 1 |
Major Players | 32 | 1 |
Julphar | 32 | 1 |
Overview | 32 | 1 |
Product Portfolio | 32 | 1 |
Research and Development | 33 | 1 |
SWOT Analysis | 33 | 4 |
Neopharma | 37 | 1 |
Overview | 37 | 1 |
Product Portfolio | 38 | 1 |
Research and Development | 39 | 1 |
SWOT Analysis | 39 | 3 |
Pfizer | 42 | 1 |
Overview | 42 | 1 |
Product Portfolio | 42 | 1 |
Research and Development | 43 | 1 |
SWOT Analysis | 44 | 6 |
GlaxoSmithKline | 50 | 1 |
Overview | 50 | 1 |
Product Portfolio | 50 | 2 |
Research and Development | 52 | 1 |
SWOT Analysis | 53 | 5 |
Novartis | 58 | 1 |
Overview | 58 | 1 |
Product Portfolio | 58 | 1 |
Research and Development | 59 | 3 |
SWOT Analysis | 62 | 6 |
Medical Device Market | 68 | 1 |
Market Overview | 68 | 1 |
Overview of the Top Five Segments | 69 | 2 |
In Vitro Diagnostics | 71 | 2 |
Ophthalmic Devices | 73 | 1 |
Orthopedic Devices | 74 | 2 |
Drug Delivery Devices | 76 | 2 |
Wound Care Management | 78 | 3 |
Major Players | 81 | 1 |
Medtronic | 82 | 1 |
Overview | 82 | 1 |
Product Portfolio | 83 | 1 |
Research and Development | 84 | 1 |
SWOT Analysis | 84 | 5 |
Siemens Healthcare | 89 | 1 |
Overview | 89 | 1 |
Product Portfolio | 90 | 1 |
Research and Development | 90 | 1 |
SWOT Analysis | 90 | 5 |
Roche | 95 | 1 |
Overview | 95 | 1 |
Product Portfolio | 96 | 1 |
Research and Development | 96 | 1 |
SWOT Analysis | 97 | 6 |
Abbott Laboratories | 103 | 1 |
Overview | 103 | 1 |
Product Portfolio | 103 | 1 |
Research and Development | 104 | 1 |
SWOT Analysis | 104 | 5 |
Boston Scientific | 109 | 1 |
Overview | 109 | 1 |
Product Portfolio | 110 | 1 |
Research and Development | 110 | 1 |
SWOT Analysis | 110 | 6 |
Market Drivers and Barriers | 116 | 1 |
Drivers | 116 | 2 |
Barriers | 118 | 2 |
Market Access | 120 | 33 |
Reimbursement and Payer Landscape | 120 | 1 |
Overview of Healthcare System | 120 | 1 |
Reimbursement Process | 121 | 4 |
Overview of Insurance Providers | 125 | 1 |
Public Insurance | 125 | 1 |
Private Insurance | 126 | 1 |
Patient Share of Healthcare Expenditure | 127 | 1 |
Healthcare Price Trends | 128 | 1 |
Pricing Policies | 129 | 2 |
Regulatory Landscape | 131 | 1 |
Overview of Regulatory Agencies | 131 | 4 |
Market Authorization Procedure for Pharmaceutical Products | 135 | 1 |
Market Authorization Procedure for New Drugs | 135 | 2 |
Market Authorization Procedure for Generic Drugs | 137 | 1 |
New Medical Device Approval Process | 138 | 2 |
Licensing Process for Pharmaceutical and Medical Device Manufacturing | 140 | 2 |
Licensing Process for Pharmaceutical Exports and Imports | 142 | 1 |
Intellectual Property Rights | 143 | 1 |
Patents | 143 | 3 |
Trademarks and Service Marks | 146 | 1 |
Clinical Trial Regulations | 147 | 2 |
Pharmaceutical Advertising Regulations | 149 | 1 |
Pharmacy Regulations | 150 | 1 |
Labeling and Packaging Regulations | 151 | 2 |
Country Analysis | 153 | 72 |
Political Environment | 153 | 1 |
Political Structure | 153 | 1 |
Analysis of the Current Political Environment | 154 | 2 |
Healthcare Policy Initiatives | 156 | 4 |
Economic Landscape | 160 | 4 |
Economic Indicators | 164 | 1 |
Gross Domestic Product | 164 | 1 |
Gross Domestic Product per Capita | 164 | 2 |
Annual Change in Gross Domestic Product | 166 | 3 |
Gross National Income | 169 | 1 |
Inflation | 170 | 1 |
Consumer Price Index | 170 | 1 |
Annual Change in Consumer Price | 171 | 1 |
Currency Exchange Rate | 172 | 1 |
Foreign Direct Investment | 173 | 1 |
Foreign Exchange Reserves | 174 | 1 |
Trade Balance | 175 | 1 |
Imports of Goods and Services | 175 | 1 |
Exports of Goods and Services | 176 | 1 |
Government Net Debt | 177 | 1 |
Major Industries | 178 | 2 |
Demographics | 180 | 1 |
Population | 180 | 2 |
Urban Rural Share | 182 | 1 |
Distribution by Age Group | 183 | 3 |
Birth Rate | 186 | 1 |
Mortality | 187 | 1 |
Leading Causes of Mortality | 188 | 2 |
Health Status by Gender and Age | 190 | 1 |
Infant mortality | 190 | 1 |
Immunization | 191 | 1 |
Causes of Mortality in Males | 192 | 1 |
Causes of Mortality in Females | 193 | 1 |
Gender Ratio | 194 | 1 |
Life Expectancy | 195 | 2 |
Education and Literacy | 197 | 3 |
Employment | 200 | 2 |
Disease Burden | 202 | 2 |
Healthcare Infrastructure | 204 | 1 |
Healthcare Facilities | 204 | 1 |
Public Private Hospitals | 205 | 2 |
Beds by Specialty | 207 | 1 |
Diagnostic Facilities | 208 | 2 |
Healthcare Parameters | 210 | 1 |
Hospital-Beds-to-Population Ratio | 210 | 1 |
Doctor-to-Population Ratio | 211 | 1 |
Environmental Health | 212 | 6 |
Healthcare Personnel | 218 | 1 |
Healthcare Expenditure | 219 | 1 |
Overview of Healthcare Expenditure | 219 | 2 |
Major Components of Healthcare Expenditure | 221 | 1 |
Public and Private Sector Share | 222 | 1 |
Spending in Pharmaceutical R&D | 223 | 1 |
Trade Associations | 223 | 1 |
Arab Union of Producers of Drugs and Medical Supplies | 223 | 1 |
Emirates Medical Association | 223 | 1 |
Pharmaceutical Research and Manufacturers Association Gulf | 223 | 1 |
Gulf Pharmaceutical Industries Association | 223 | 1 |
Middle East Medical Devices and Diagnostics Trade Association | 224 | 1 |
Trade Fairs | 224 | 1 |
Opportunities and Challenges | 225 | 3 |
Opportunities | 225 | 1 |
Challenges | 226 | 2 |
Appendix | 228 | 24 |
Abbreviations | 228 | 2 |
Bibliography | 230 | 18 |
Research Methodology | 248 | 3 |
Coverage | 248 | 1 |
Secondary Research | 249 | 1 |
Forecasts | 250 | 1 |
Expert Panel | 250 | 1 |
Disclaimer | 250 | 2 |